<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-ZYHDBAOU</identifier><date>2012</date><creator>Matos, Erika</creator><relation>documents/doc/Z/URN_NBN_SI_doc-ZYHDBAOU_001.htm</relation><relation>documents/doc/Z/URN_NBN_SI_doc-ZYHDBAOU_001.pdf</relation><relation>documents/doc/Z/URN_NBN_SI_doc-ZYHDBAOU_001.txt</relation><format format_type="issue">3</format><format format_type="volume">81</format><format format_type="type">article</format><format format_type="extent">str. 236-245</format><identifier identifier_type="COBISSID">1245051</identifier><identifier identifier_type="ISSN">1318-0347</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-ZYHDBAOU</identifier><language>slv</language><publisher>Slovensko zdravniško društvo</publisher><source>Zdravniški vestnik</source><rights>BY-NC</rights><subject language_type_id="eng">Antibodies, monoclonal</subject><subject language_type_id="eng">Breast neoplasms</subject><subject language_type_id="eng">Drug therapy</subject><subject language_type_id="eng">Genes, ERBB-2</subject><subject language_type_id="eng">Neoplasms metastasis</subject><subject language_type_id="slv">onkologija</subject><subject language_type_id="slv">rak dojke</subject><subject language_type_id="eng">Survival analysis</subject><subject language_type_id="slv">tarčno zdravljenje</subject><subject language_type_id="slv">trastuzumab</subject><title>Treatment of HER2 positive breast cancer patients</title><title>Zdravljenje bolnic s HER2-pozitivnim rakom dojk</title></Record>